Antagonists of A2B Receptors Improve Insulin Sensitivity

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$1,424,440.00
Award Year:
2004
Program:
SBIR
Phase:
Phase II
Contract:
2R44DK059677-02
Agency Tracking Number:
1R43DK059677-01
Solicitation Year:
2004
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2004-2
Small Business Information
ADENOSINE THERAPEUTICS, LLC
310 FOURTH STREET NE, SUITE 201, CHARLOTTESVILLE, VA, 22902
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
ROBERT Figler
(434) 924-5427
RAF@ADENRX.COM
Business Contact:
(434) 220-9400
ROB@ADENRX.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): This is a phase II SBIR grant to develop a new therapy for the treatment of type II diabetes. Adenosine Therapeutics, LLC (ATL) is a biotechnology company started in Charlottesville, Virginia in 1999. ATL owns patents

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government